Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma
Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma
5. QST in patients with tendinopathy 2.4. Statistical analyses The data of the thirteen measurements of QST in the injured athletes were compared to the healthy controls. Since some of the QST outcomes are ordinal data and most data were non-normally divided we used non-parametric tests (Mann Whitney U). The descriptive data of the social demographic parameters are presented. Because of nonnormally divided data the SCL-90 and POMS dimensions were analyzed using nonparametric (Mann Whitney U) test to compare injured versus control athletes. 3. Results 3.1. Participants The socio-demographic data are presented in Table 5-1; twelve PT patients and 20 control athletes were included in the study. All athletes were still training and or playing matches. The outcome on the VISA-P differed significantly between patients (VISA-P 62, SD 17.97) and controls (VISA-P 99, SD 1.68). The median duration of symptoms for the PT group was 30 months (range 6 - 120). The outcome of QST assessment is presented in Table 5-2. Table 5-1: Socio demographic data of patients with a patella tendinopathy to healthy controls 3.2. QST In two of the thirteen QST parameters i.e. mechanical pain threshold and vibration disappearance threshold injured athletes were significantly more sensitive for the applied stimuli than for the control group (Table 5-2). None of the athletes showed signs of dynamic mechanical allodynia (DMA). The room temperature during QST testing was 23.7°C (SD 0.8).
5. QST in patients with tendinopathy Table 5-2: Results on the Mann Whitney test; comparing QST data of patients with a patella tendinopathy to healthy controls - * intensity of perception of series of 1Hz vs. single, ** numeric rating scale 0-100
- Page 36 and 37: 2. Bilateral abnormalities in neuro
- Page 38 and 39: 2. Bilateral abnormalities in neuro
- Page 40 and 41: 2. Bilateral abnormalities in neuro
- Page 42 and 43: 2. Bilateral abnormalities in neuro
- Page 44 and 45: 2. Bilateral abnormalities in neuro
- Page 46: 2. Bilateral abnormalities in neuro
- Page 49 and 50: 3. Somatosensory function and neuro
- Page 51 and 52: 0 3. Somatosensory function and neu
- Page 53 and 54: 3. Somatosensory function and neuro
- Page 55 and 56: 3. Somatosensory function and neuro
- Page 57 and 58: 3. Somatosensory function and neuro
- Page 59 and 60: 3. Somatosensory function and neuro
- Page 61 and 62: 3. Somatosensory function and neuro
- Page 63 and 64: 3. Somatosensory function and neuro
- Page 65 and 66: 3. Somatosensory function and neuro
- Page 67 and 68: 4. QST and neuropathic pain mechani
- Page 69 and 70: 4. QST and neuropathic pain mechani
- Page 71 and 72: 4. QST and neuropathic pain mechani
- Page 73 and 74: 4. QST and neuropathic pain mechani
- Page 75 and 76: 4. QST and neuropathic pain mechani
- Page 77 and 78: 4. QST and neuropathic pain mechani
- Page 79 and 80: 4. QST and neuropathic pain mechani
- Page 81 and 82: 5. QST in patients with tendinopath
- Page 83 and 84: 5. QST in patients with tendinopath
- Page 85: 5. QST in patients with tendinopath
- Page 89 and 90: 5. QST in patients with tendinopath
- Page 91 and 92: 5. QST in patients with tendinopath
- Page 94 and 95: Chapter 6 General discussion and Su
- Page 96 and 97: 6. General discussion and Summary s
- Page 98 and 99: 6. General discussion and Summary s
- Page 100 and 101: 6. General discussion and Summary T
- Page 102 and 103: 6. General discussion and Summary Q
- Page 104 and 105: 6. General discussion and Summary S
- Page 106 and 107: References Abate M, Silbernagel KG,
- Page 108 and 109: de la Llave-Rincon AI, Fernandez-de
- Page 110 and 111: Kehlet H, Jensen TS, Woolf CJ. 2006
- Page 112 and 113: Robinson JM, Cook JL, Purdam C, Vis
- Page 114 and 115: Visentini PJ, Khan KM, Cook JL, Kis
- Page 116 and 117: Nederlandse samenvatting Met de ont
- Page 118 and 119: Acknowledgement To produce a work s
5. <strong>QST</strong> in patients with tendinopathy<br />
2.4. Statistical analyses<br />
The data of the thirteen measurements of <strong>QST</strong> in the injured athletes were compared<br />
to the healthy controls. Since some of the <strong>QST</strong> outcomes are ordinal data and most<br />
data were non-normally divided we used non-parametric tests (Mann Whitney U). The<br />
descriptive data of the social demographic parameters are presented. Because of nonnormally<br />
divided data the SCL-90 and POMS dimensions were analyzed using nonparametric<br />
(Mann Whitney U) test to compare injured versus control athletes.<br />
3. Results<br />
3.1. Participants<br />
The socio-demographic data are presented in Table 5-1; twelve PT patients and 20<br />
control athletes were included in the study. All athletes were still training and or playing<br />
matches. The outcome on the VISA-P differed significantly between patients (VISA-P<br />
62, SD 17.97) and controls (VISA-P 99, SD 1.68). The median duration of symptoms<br />
for the PT group was 30 months (range 6 - 120). The outcome of <strong>QST</strong> assessment is<br />
presented in Table 5-2.<br />
Table 5-1: Socio demographic data of patients with a patella tendinopathy to healthy controls<br />
3.2. <strong>QST</strong><br />
In two of the thirteen <strong>QST</strong> parameters i.e. mechanical pain threshold and vibration<br />
disappearance threshold injured athletes were significantly more sensitive for the<br />
applied stimuli than for the control group (Table 5-2). None of the athletes showed signs<br />
of dynamic mechanical allodynia (DMA). The room temperature during <strong>QST</strong> testing<br />
was 23.7°C (SD 0.8).